Thelansis

Follicular lymphoma, constituting 20-30% of all non-Hodgkin lymphomas, is the most prevalent subtype of low-grade (indolent) lymphoma. Its etiology remains unknown, ruling out infection as a causative factor and eliminating its potential for contagion. B-cell lymphoma, known as follicular lymphoma, is identified by tumor cells organized in a circular or clustered arrangement under microscopic examination. These anomalous follicles supplant the typical lymph node structure. Notably, over 90% of individuals with follicular lymphoma exhibit the CD20 protein on the surface of the malignant follicular cells, rendering them susceptible to certain treatment approaches. Prognosis and risk assessment for follicular lymphoma hinge on factors derived from the FLIP2 study, including Beta2 microglobulin exceeding the upper limit of normal, bone marrow involvement, hemoglobin levels below 12g/dL, the largest involved node's diameter exceeding 6 cm, and an age surpassing 60 years. The five-year p...

 Follicular lymphoma (FL), commonly referred to as indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. The introduction of anti-CD20 monoclonal antibodies (mAb) such as rituximab and, more recently, the type II anti-CD20 mAb, obinutuzumab, have revolutionized the management of FL, and anti-CD20 antibodies will likely remain at the forefront of the FL treatment armamentarium. But more recent insights demonstrating the intricate relationship between the FL tumor cell and its distinct immune microenvironment have led to a rapid accumulation of novel and innovative targeted therapies that harness the immune system's power to attack the malignant cell. ·        Follicular lymphoma (FL) affects approxi...

  Follicular lymphoma (FL), commonly referred to as indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. The introduction of anti-CD20 monoclonal antibodies (mAb) such as rituximab, and, more recently the type II anti-CD20 mAb, obinutuzumab, have revolutionized the management of FL and it is likely that anti-CD20 antibodies will remain at the forefront of the FL treatment armamentarium. But more recent insights demonstrating the intricate relationship between the FL tumor cell and its distinct immune microenvironment have led to a rapid accumulation of novel and innovative targeted therapies that harness the power of the immune system to attack the malignant cell. FL affects approximately 3.7 in 10,000 individuals in the Europ...